Rapport Therapeutics Reports Third Quarter 2026 Financials and Provides Business Update
Globe Newswire•04/11/2026•07:00 ET
0
Key Highlights
- ➤RAP-219 Phase 2 bipolar mania trial met primary and secondary endpoints
- ➤RAP-219 bipolar mania Phase 3 initiation expected in second half of 2027
- ➤RAP-219 Phase 3 focal-onset-seizure trials are enrolling patients
- ➤Rapport ended Q3 with $395.0 million cash, equivalents and investments
- ➤Rapport expects $815.4 million and runway through end of 2029
Expert Statements
Abraham N. Ceesay, Chief Executive Officer of Rapport Therapeutics
“We continue to deliver on our priorities with strong execution across the portfolio.”
Abraham N. Ceesay, Chief Executive Officer of Rapport Therapeutics
“Our positive Phase 2 results in bipolar mania are transformational for Rapport, accelerating our path to becoming an industry-leading precision neuroscience company.”
Abraham N. Ceesay, Chief Executive Officer of Rapport Therapeutics
“RAP-219 now has clinical proof-of-concept in two indications across neurology and psychiatry, giving us the opportunity to serve patients in two multibillion-dollar markets.”
Abraham N. Ceesay, Chief Executive Officer of Rapport Therapeutics
“We are building on this momentum, with a steady cadence of catalysts ahead.”
Abraham N. Ceesay, Chief Executive Officer of Rapport Therapeutics
“With the additional capital from our recent financing, we are well funded to deliver on the catalysts ahead and remain committed to delivering sustained value for both patients and shareholders.”
Positive topline results from Phase 2 trial of RAP-219 in bipolar mania; initiation of two Phase 3 trials in bipolar mania expected in 2H 2027
Data from the Phase 2 FOS open-label long-term safety trial expected in 4Q 2026; Phase 3 FOS trials enrolling patients
Get started
Create a free account to read the full story.